Juno Therapeutics (JUNO) : Zacks Investment Research ranks Juno Therapeutics (JUNO) as 4, which is a Sell recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.78, which indicates as a Buy.
Juno Therapeutics (JUNO) : The highest level Juno Therapeutics (JUNO) is projected to reach is $80 for the short term and the lowest estimate is at $39. The consolidated price target from 9 rating analysts who initiate coverage on the stock is $52.67 and the possibility the share price can swing is $12.75.
For the current week, the company shares have a recommendation consensus of Buy.
Juno Therapeutics (NASDAQ:JUNO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.49 and $30.32 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $31.45. The buying momentum continued till the end and the stock did not give up its gains. It closed at $31.31, notching a gain of 2.05% for the day. The total traded volume was 1,003,266 . The stock had closed at $30.68 on the previous day.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.